Are GP practice prescribing rates for coronary heart disease drugs equitable? A cross sectional analysis in four primary care trusts in England

Journal of Epidemiology and Community Health

Volumn 58, Issue 2, 2004, Pages 89-96

  Ward, P R ^a   Noyce, P R ^b   St Leger, A S ^b  

^a SHEFFIELD HALLAM UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ATENOLOL; ATENOLOL PLUS CHLORTALIDONE; ATORVASTATIN; BENDROFLUMETHIAZIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; CERIVASTATIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LISINOPRIL; PRAVASTATIN; RAMIPRIL; SIMVASTATIN; TRANDOLAPRIL;

PRIMARY HEALTH CARE;

ADULT; AGE; AGED; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG COST; ETHNOLOGY; GENERAL PRACTICE; HEALTH CARE COST; HEALTH CARE NEED; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; PRESCRIPTION; PRIMARY MEDICAL CARE;

AGE FACTORS; CORONARY DISEASE; CROSS-SECTIONAL STUDIES; ENGLAND; ETHNIC GROUPS; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; PRESCRIPTIONS, DRUG; SOCIOECONOMIC FACTORS;

EID: 1642521017     PISSN: 0143005X     EISSN: None     Source Type: Journal    
DOI: 10.1136/jech.58.2.89     Document Type: Article

References (49)

1. Department of Health. National Service Frameworks for coronary heart disease. London: Stationery Office, 2000.
2. MacLeod MC, Finlayson AR, Pell JP, et al. Geographic, demographic, and socioeconomic variations in the investigation and management of coronary heart disease in Scotland. Heart 1999;81:252-6.
3. Majeed FA, Cook D. Age and sex differences in the management of ischaemic heart disease. Public Health 1996;110:7-12.
4. Gatrell A, Lancaster G, Chapple A, et al. Variations in use of tertiary cardiac services in part of North-West England. Health & Place 2002;8:147-53.
5. Dong W, Ben-Shlomo Y, Colhoun H, et al. Gender differences in accessing cardiac surgery across England: a cross-sectional analysis of the health survey for England. Soc Sci Med 1998;47:1773-80.
6. Hippisley-Cox J, Pringle M, Crown N, et al. Sex inequalities in ischaemic heart disease in general practice: cross sectional survey. BMJ 2001;322:832.
7. Majeed FA, Chaturvedi N, Reading R, et al. Equity in the NHS. Monitoring and promoting equity in primary and secondary care. BMJ 1994;308:1426-9.
8. Majeed A, Eliahoo J, Bardsley M, et al. Variation in coronary artery bypass grafting, angioplasty, cataract surgery, and hip replacement rates among primary care groups in London: association with population and practice characteristics. J Public Health Med 2002;24:21-6.
9. Payne N, Saul C. Variations in use of cardiology services in a health authority: comparison of coronary artery revascularisation rates with prevalence of angina and coronary mortality. BMJ 1997;314:257-61.
10. Ancona C, Agabiti N, Forastiere F, et al. Coronary artery bypass graft surgery: socioeconomic inequalities in access and in 30 day mortality. A population-based study in Rome, Italy. J Epidemiol Community Health 2000;54:930-5.
11. Hippisley-Cox J, Pringle M. Inequalities in access to coronary angiography and revascularisation: the association of deprivation and location of primary care services. Br J Gen Pract 2000;50:449-54.
12. NHS Executive. Review of invasive cardiac services in the North West Region. Warrington: NHS Executive, 1996.
13. Bradshaw J. A taxonomy of social need. In: McLachlan G, ed. Problems and progress in medical care. Oxford: Nuffield Provincial Hospital Trust, 1972.
14. Bradshaw J. The conceptualisation and measurement of need. In: Popay J, ed. Researching the people's health. London: Routledge, 1994:45-57.
15. Rice N, Dixon P, Lloyd DC, et al. Derivation of a needs based capitation formula for allocating prescribing budgets to health authorities and primary care groups in England: regression analysis. BMJ 2000;320:284-8.
16. Lloyd DC, Scrivener G. Prescribing at the Primary Care Group level: census data and prescribing indicators. J Clin Pharm Ther 2001;26:93-101.
17. Majeed A, Cook DG, Evans N. Variations in general practice prescribing costs-implications for setting and monitoring prescribing budgets. Health Trends 1996;28:52-5.
18. Morton-Jones T, Pringle M. Explaining variations in prescribing costs across England. BMJ 1993;306:1731-4.
19. Pringle M, Morton-Jones T. Using unemployment rates to predict prescribing trends in England. Br J Gen Pract 1994;44:53-6.
20. Primatesta P, Poulter NR. Lipid concentrations and the use of lipid lowering drugs: evidence from a national cross sectional survey. BMJ 2000;321:1322-5.
21. Packham C, Pearson J, Robinson J, et al. Use of statins in general practices, 1996-8: cross sectional study. BMJ 2000;320:1583-4.
22. Packham C, Robinson J, Morris J, et al. Statin prescribing in Nottingham general practices: a cross-sectional study. J Public Health Med 1999;21:60-4.
23. Reid FDA, Cook DG, Whincup PH. Use of statins in the secondary prevention of coronary heart disease: is treatment equitable? Heart 2002;88:15-9.
24. Baxter C, Jones R, Corr L. Time trend analysis and variations in prescribing lipid lowering drugs in general practice. BMJ 1998;317:1134-5.
25. Majeed A, Moser K, Maxwell R. Age, sex and practice variations in the use of statins in general practice in England and Wales. J Public Health Med 2000;22:275-9.
26. Gibson A, Asthana S, Brigham P, et al. Geographies of need and the new NHS: methodological issues in the definition and measurement of the health needs of local populations. Health & Place 2002;8:47-60.
27. Danchin N, Grenier O, Ferrieres J, et al. Use of secondary preventive drugs in patients with acute coronary syndromes treated medically or with coronary angioplasty: results from the nationwide French PREVENIR survey. Heart 2002;88:159-62.
28. Wang TJ, Stafford RS. National patterns and predictors of beta-blocker use in patients with coronary artery disease. Arch Intern Med 1998;158:1901-6.
29. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 1998;339:489-97.
30. Whincup PH, Emberson JR, Lennon L, et al. Low prevalence of lipid lowering drug use in older men with established coronary heart disease. Heart 2002;88:25-9.
31. Patel MG, Wright DJ, Gill PS, et al. Prescribing of lipid lowering drugs to South Asian patients: ecological study. BMJ 2002;325:25-6.
32. Bradshaw N, Fone DL, Walker R. Explaining variation in statin prescribing: a practice based analysis. Pharm J 1999;263:R19.
33. Bradshaw N, Fone DL, Walker R. Equity of health care: a ward-based analysis of primary care prescribing. Pharm J 1998;261:R11.
34. Salomaa V, Miettinen H, Niemela M, et al. Relation of socioeconomic position to the case fatality, prognosis and treatment of myocardial infarction events; the FINMONICA MI Register Study. J Epidemiol Community Health 2001;55:475-82.
35. Suadicani P, Hein HO, Gyntelberg F. Socioeconomic status and ischaemic heart disease mortality in middle- aged men: importance of the duration of follow-up. The Copenhagen Male Study. Int J Epidemiol 2001;30:248-55.
36. Frischer M, Chapman SR. Issues and directions in prescribing analysis. In: Panton R, Chapman SR, eds. Medicines management. London: Pharmaceutical Press, 1998.
37. Bogle SM, Harris CM. Measuring prescribing: the shortcomings of the item. BMJ 1994;308:637-40.
38. Walley T, Roberts DJ. Average daily quantities: a tool for measuring prescribing volume in England. Pharmacoepidemiol Drug Safety 2000;9:55-8.
39. Prescribing Support Unit. Defined daily doses, prescribed daily doses and average daily quantities. Leeds: Prescribing Support Unit, 1997.
40. Prescribing Support Unit. Average daily quantities and STAR(97)-PUs. Leeds: PSU, 2000.
41. Office for National Statistics. Key statistics from general practice. London: ONS, 2000.
42. Majeed FA, Cook DG, Poloniecki J, et al. Using data from the 1991 census. BMJ 1995;310:1511-14.
43. Haynes RM, Lovett AA, Gale SH, et al. Evaluation of methods for calculating census health indicators for GP practices. Public Health 1995;109:369-74.
44. Crayford T, Shanks J, Bajekal M, et al. Analysis from Inner London of deprivation payments based on enumeration districts rather than wards. BMJ 1995;311:787-8.
45. Townsend P, Phillimore P, Beattie A. Health and deprivation: inequality and the north. London: Croon Helm, 1988.
46. Lloyd DC, Harris CM, Clucas DW. Low income scheme index: a new deprivation scale based on prescribing in general practice. BMJ 1995;310:165-9.
47. Ward PR, Noyce PR, St Leger AS. Developing prevalence-based prescribing units for analysing variations in general practitioner prescribing: a case study using statins. J Clin Pharm Ther 2003;28:23-30.
48. Office for National Statistics. Key statistics from general practice. Table 6A1: Prevalence of treated CHD per 1000 patients by age, sex and country/region-1994-1998. London: ONS, 2000.
49. British Heart Foundation. Coronary heart disease statistics. BHF database 2002. http://www.dphpc.ox.ac.uk/bhfprg/stats/2000/2002/index/html.